Insider · SEC Form 4 filer

Leon Moulder

Past buys: 3 of 5 beat

Companies

Where they file as an insider

Zai Lab (ZLAB) Director Latest filing Jun 17, 2026

Zenas BioPharma (ZBIO) CEO, Director Latest filing May 18, 2026

Dianthus Therapeutics (DNTH) Director Latest filing Jan 22, 2024

Track record

Did their buys beat the typical stock?

Open-market buys19

Quarters checked 6 months later5

Beat the typical stock 3 of 5

Quarters too new to check1

3 of 5 checked quarters beat the typical stock. A past record is data, not a forecast.

Zenas BioPharma (ZBIO) Bought Apr 28–May 18, 2026 · $2.08M · 120,000 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.

Zenas BioPharma (ZBIO) Bought Jan 7–Mar 31, 2026 · $3.68M · 211,000 shares Beat typical Mar 31, 2026 $19.55 → Sep 30, 2026 $26.97 · +38.0% (typical stock +1.7%)

Zenas BioPharma (ZBIO) Bought Oct 7, 2025 · $770K · 36,928 shares Behind typical Dec 31, 2025 $36.31 → Jun 30, 2026 $25.38 · −30.1% (typical stock +4.7%)

Zenas BioPharma (ZBIO) Bought Feb 18, 2025 · $167K · 25,000 shares Beat typical Mar 31, 2025 $7.90 → Sep 30, 2025 $22.20 · +181.0% (typical stock +7.3%)

Zenas BioPharma (ZBIO) Bought Nov 18–Dec 4, 2024 · $867K · 80,000 shares Beat typical Dec 31, 2024 $8.19 → Jun 30, 2025 $9.69 · +18.3% (typical stock −3.4%)

Zenas BioPharma (ZBIO) Bought Sep 18–20, 2024 · $361K · 20,000 shares Behind typical Sep 30, 2024 $16.92 → Mar 31, 2025 $7.90 · −53.3% (typical stock −7.5%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Leon Moulder

Where they file as an insider

Did their buys beat the typical stock?

Free weekly email